Drug intelligence / Profile preview

Bugan Shengjiang Tang

Development stage: Preclinical
Lead developer: Ankang Traditional Chinese Medicine Hospital
Administration: Oral

Overview

Bugan Shengjiang Tang is a traditional Chinese medicine formula being investigated for the treatment of acute-on-chronic liver failure. It is studied for its role in regulating liver cell regeneration through the "CSS/MD" signal pathway, based on the theory of Xianghuo Shengfa. It is administered orally and has been evaluated in clinical trials in combination with artificial liver support systems.

Other names: 补肝升降汤

Beyond the preview

Go deeper on Bugan Shengjiang Tang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bugan Shengjiang Tang.

Explore the full profile